摘要 |
Methods of identifying therapeutic agents that inhibit, potentiate or mimic the ability of a km23 polypeptide mutant form, or a nucleic acid encoding the mutant form to modulate the signal transduction activity of a growth factor or cytokine are provided. The methods involve treating a cell with a candidate compound so as to alter at least one cell process associated with the TGF&bgr; signaling pathway, and measuring the effect of the candidate on the cell. Further provided are cell and non-cell based methods of screening for a therapeutic agent that inhibits or stimulates the interaction of an altered form of wild-type km23 with a specific binding protein, such as the dynein intermediate chain (DIC), Smad2 or RI and RII TGF&bgr; receptors. These methods involve determining the inhibition or stimulation of a therapeutic candidate on the interaction of the specific binding protein with the km23 altered form. The km23 mutant/altered forms of the methods of the present invention indicate an increased risk of ovarian cancer.
|